Gene "CYSLTR2"
Found 4 records
Gene information
Gene symbol:
CYSLTR2
See related:
Ensembl: ENSG00000152207, Gene ID: 57105
Additive variants :
Undetected
Genetic interaction partners
No data
Modifier statisitcs
Record:
4 
Disorder:
1 
Vriant:
2 
Reference:
2 
Effect type:
Expressivity(4)  
Modifier effect:
Altered morning PEF(2) ,Altered response to montelukast(2)  
Details：
  • Variant 1:
    CYSLTR2:rs91227
    Gene:
    CYSLTR2
    Genomic location:
    dbSNP ID:
    rs91227
    Target disease:
    Asthma(DOID_2841)
    Effect type:
    Expressivity 
    Modifier effect:
    Altered morning PEF 
    Evidence:
    From review article 
    Effect:
    Mutations in CYSLT2 is Associated with morning PEF in subjects taking montelukast
    Reference:
    PMID22455494
    Title:
    Genetic basis for personalized medicine in asthma.
    Species studied:
    Human
    Abstract:
    There is heterogeneity in patient responses to current asthma medications. Significant progress has been made identifying genetic polymorphisms that influence the efficacy and potential for adverse effects to asthma drugs, including; β(2)-adrenergic receptor agonists, corticosteroids and leukotriene modifiers. Pharmacogenetics holds great promise to maximise clinical outcomes and minimize adverse effects. Asthma is heterogeneous with respect to clinical presentation and inflammatory mechanisms underlying the disease, which is likely to contribute to variable results in clinical trials targeting specific inflammatory mediators. Genome-wide association studies have begun to identify genes underlying asthma (e.g., IL1RL1), which represent future therapeutic targets. In this article, we review and update the pharmacogenetics of current asthma therapies and discuss the genetics underlying selected Phase II and future targets.
  • Variant 2:
    CYSLTR2:rs91227
    Gene:
    CYSLTR2
    Genomic location:
    dbSNP ID:
    rs91227
    Target disease:
    Asthma(DOID_2841)
    Effect type:
    Expressivity 
    Modifier effect:
    Altered response to montelukast 
    Evidence:
    P=0.02 
    Effect:
    CYSLTR2 and ALOX5 polymorphisms may predispose a minority of individuals to excessive cysteinyl-leukotriene concentrations, yielding a distinct asthma phenotype most likely to respond to leukotriene modifier pharmacotherapy.
    Reference:
    PMID17460547
    Title:
    Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast.
    Species studied:
    Human
    Abstract:
    Interindividual clinical response to leukotriene modifiers is highly variable, and less efficacious than inhaled corticosteroids in treating asthma. Genetic variability in 5-lipoxygenase biosynthetic and receptor pathway gene loci may influence cysteinyl-leukotriene production and subsequent response to leukotriene modifiers.
  • Variant 3:
    CYSLTR2:c.*1493A>G
    Gene:
    CYSLTR2
    Genomic location:
    chr13:49283487
    dbSNP ID:
    rs912278
    Target disease:
    Asthma(DOID_2841)
    Effect type:
    Expressivity 
    Modifier effect:
    Altered morning PEF 
    Evidence:
    From review article 
    Effect:
    Mutations in CYSLT2 is Associated with morning PEF in subjects taking montelukast
    Reference:
    PMID22455494
    Title:
    Genetic basis for personalized medicine in asthma.
    Species studied:
    Human
    Abstract:
    There is heterogeneity in patient responses to current asthma medications. Significant progress has been made identifying genetic polymorphisms that influence the efficacy and potential for adverse effects to asthma drugs, including; β(2)-adrenergic receptor agonists, corticosteroids and leukotriene modifiers. Pharmacogenetics holds great promise to maximise clinical outcomes and minimize adverse effects. Asthma is heterogeneous with respect to clinical presentation and inflammatory mechanisms underlying the disease, which is likely to contribute to variable results in clinical trials targeting specific inflammatory mediators. Genome-wide association studies have begun to identify genes underlying asthma (e.g., IL1RL1), which represent future therapeutic targets. In this article, we review and update the pharmacogenetics of current asthma therapies and discuss the genetics underlying selected Phase II and future targets.
  • Variant 4:
    CYSLTR2:c.*1493A>G
    Gene:
    CYSLTR2
    Genomic location:
    chr13:49283487
    dbSNP ID:
    rs912278
    Target disease:
    Asthma(DOID_2841)
    Effect type:
    Expressivity 
    Modifier effect:
    Altered response to montelukast 
    Evidence:
    P=0.02 
    Effect:
    CYSLTR2 and ALOX5 polymorphisms may predispose a minority of individuals to excessive cysteinyl-leukotriene concentrations, yielding a distinct asthma phenotype most likely to respond to leukotriene modifier pharmacotherapy.
    Reference:
    PMID17460547
    Title:
    Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast.
    Species studied:
    Human
    Abstract:
    Interindividual clinical response to leukotriene modifiers is highly variable, and less efficacious than inhaled corticosteroids in treating asthma. Genetic variability in 5-lipoxygenase biosynthetic and receptor pathway gene loci may influence cysteinyl-leukotriene production and subsequent response to leukotriene modifiers.